Health Trials

RFA Plus Carrizumab vs Carrizumab Alone for HCC

ConditionsTumor ImmunityImmunosuppressionRadiofrequency Ablation
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18-75
SponsorSecond Affiliated Hospital, School of Medicine, Zhejiang University

About this trial

The study aims to find whether patients with advanced HCC can get more benefits from RFA +PD-1 immunosuppressant (carrizumab) compared with carrizumab alone, considering with the result of PFS.

Eligibility criteria

Qualifiers

Age from 18-75 years

Diagnosis as hepatocellular carcinoma from histology and cytology

BCLC B-C degree

Score of ECOG PS: 0-2

Disqualifiers

Have cholangiocarcinoma, mixed type of hepatocarcinoma and fibrolamellar hepatocellular carcinoma. Have incurable malignant tumor in five years.

Have local ablation, TACE or radiotherapy in 3 months before enrolled.

Prepared to or have received organic or bone marrow transplantation.

Uncontrollable ascites, hepatic encephalopathy or esophageal and gastric varices.

Trial design

Treatments tested in this trial

  • radiofrequency ablation

Treatment groups

120 Participants
are divided into 2 treatment groups

Sponsors and collaborators

Second Affiliated Hospital, School of Medicine, Zhejiang University

Lead sponsor

Source ClinicalTrials.gov